These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 27259252)
1. Virus-stimulated neutrophils in the tumor microenvironment enhance T cell-mediated anti-tumor immunity. Chang CY; Tai JA; Li S; Nishikawa T; Kaneda Y Oncotarget; 2016 Jul; 7(27):42195-42207. PubMed ID: 27259252 [TBL] [Abstract][Full Text] [Related]
2. CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy. Pan YC; Nishikawa T; Chang CY; Tai JA; Kaneda Y Mol Ther Oncolytics; 2021 Mar; 20():175-186. PubMed ID: 33575480 [TBL] [Abstract][Full Text] [Related]
3. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma. Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337 [TBL] [Abstract][Full Text] [Related]
4. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Kurooka M; Kaneda Y Cancer Res; 2007 Jan; 67(1):227-36. PubMed ID: 17210703 [TBL] [Abstract][Full Text] [Related]
5. The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma. Kiyohara E; Tamai K; Katayama I; Kaneda Y Gene Ther; 2012 Jul; 19(7):734-41. PubMed ID: 21900962 [TBL] [Abstract][Full Text] [Related]
6. Recent advances and developments in the antitumor effect of the HVJ envelope vector on malignant melanoma: from the bench to clinical application. Tanemura A; Kiyohara E; Katayama I; Kaneda Y Cancer Gene Ther; 2013 Nov; 20(11):599-605. PubMed ID: 24157924 [TBL] [Abstract][Full Text] [Related]
7. Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma. Takehara Y; Satoh T; Nishizawa A; Saeki K; Nakamura M; Masuzawa M; Kaneda Y; Katayama I; Yokozeki H Clin Immunol; 2013 Oct; 149(1):1-10. PubMed ID: 23886549 [TBL] [Abstract][Full Text] [Related]
9. A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy. Kawano H; Komaba S; Kanamori T; Kaneda Y BMC Med; 2007 Sep; 5():28. PubMed ID: 17883878 [TBL] [Abstract][Full Text] [Related]
10. Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma. Matsuda M; Nimura K; Shimbo T; Hamasaki T; Yamamoto T; Matsumura A; Kaneda Y J Neurooncol; 2011 May; 103(1):19-31. PubMed ID: 20730616 [TBL] [Abstract][Full Text] [Related]
11. Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Kawaguchi Y; Miyamoto Y; Inoue T; Kaneda Y Int J Cancer; 2009 May; 124(10):2478-87. PubMed ID: 19173282 [TBL] [Abstract][Full Text] [Related]
12. Inactivated Sendai virus particle upregulates cancer cell expression of intercellular adhesion molecule-1 and enhances natural killer cell sensitivity on cancer cells. Li S; Nishikawa T; Kaneda Y Cancer Sci; 2017 Dec; 108(12):2333-2341. PubMed ID: 28945328 [TBL] [Abstract][Full Text] [Related]
13. Salmonella mediated the hemagglutinating virus of Japan-envelope transfer suppresses tumor growth. Lee CH; Nishikawa T; Kaneda Y Oncotarget; 2017 May; 8(21):35048-35060. PubMed ID: 28456782 [TBL] [Abstract][Full Text] [Related]
14. [Anticancer immunotherapy using inactivated Sendai virus particles]. Kurooka M; Kaneda Y Uirusu; 2007 Jun; 57(1):19-27. PubMed ID: 18040151 [TBL] [Abstract][Full Text] [Related]